[go: up one dir, main page]

MX2016000235A - Metodos y composiciones para vacunas del virus del dengue. - Google Patents

Metodos y composiciones para vacunas del virus del dengue.

Info

Publication number
MX2016000235A
MX2016000235A MX2016000235A MX2016000235A MX2016000235A MX 2016000235 A MX2016000235 A MX 2016000235A MX 2016000235 A MX2016000235 A MX 2016000235A MX 2016000235 A MX2016000235 A MX 2016000235A MX 2016000235 A MX2016000235 A MX 2016000235A
Authority
MX
Mexico
Prior art keywords
dengue virus
methods
compositions
virus vaccines
glycoprotein
Prior art date
Application number
MX2016000235A
Other languages
English (en)
Other versions
MX365957B (es
Inventor
Messer William
Baric Ralph
DESILVA Aravinda
Yount Boyd
Original Assignee
Univ North Carolina Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina Chapel Hill filed Critical Univ North Carolina Chapel Hill
Publication of MX2016000235A publication Critical patent/MX2016000235A/es
Publication of MX365957B publication Critical patent/MX365957B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1825—Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
    • C07K16/116—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)

Abstract

|La presente invención provee composiciones y métodos de uso que comprenden una glucoproteína E quimérica del virus del dengue que comprende una estructura de base de glucoproteína E del virus del dengue, la cual comprende sustituciones de aminoácido que introducen un epítopo que es reconocido por un anticuerpo de un serotipo del virus del dengue que es diferente del serotipo de virus del dengue de la estructura de base de glucoproteína E del virus del dengue.
MX2016000235A 2013-06-26 2014-06-26 Métodos y composiciones para vacunas del virus del dengue. MX365957B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361839687P 2013-06-26 2013-06-26
PCT/US2014/044410 WO2014210358A1 (en) 2013-06-26 2014-06-26 Methods and compositions for dengue virus vaccines

Publications (2)

Publication Number Publication Date
MX2016000235A true MX2016000235A (es) 2016-08-11
MX365957B MX365957B (es) 2019-06-20

Family

ID=52142690

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016000235A MX365957B (es) 2013-06-26 2014-06-26 Métodos y composiciones para vacunas del virus del dengue.
MX2019007252A MX2019007252A (es) 2013-06-26 2016-01-07 Metodos y composiciones para vacunas del virus del dengue.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019007252A MX2019007252A (es) 2013-06-26 2016-01-07 Metodos y composiciones para vacunas del virus del dengue.

Country Status (12)

Country Link
US (2) US10053493B2 (es)
EP (2) EP3013852B1 (es)
JP (2) JP6525984B2 (es)
KR (1) KR20160027019A (es)
CN (2) CN110734500A (es)
AU (2) AU2014302282B2 (es)
BR (1) BR112015032388A8 (es)
CA (1) CA2918644A1 (es)
ES (1) ES2745431T3 (es)
MX (2) MX365957B (es)
SG (1) SG11201510617WA (es)
WO (1) WO2014210358A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015338859A1 (en) * 2014-11-02 2017-06-01 The University Of North Carolina At Chapel Hill Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
TWI769185B (zh) * 2016-10-27 2022-07-01 海樂源有限公司 登革熱類病毒顆粒、抗登革熱病毒抗體、及含其之組合物
WO2018217906A1 (en) * 2017-05-23 2018-11-29 The University Of North Carolina At Chapel Hill Methods and compositions for dengue virus serotype 4 epitopes
WO2018231974A1 (en) * 2017-06-14 2018-12-20 Thomas Jefferson University Composition and administration of chimeric glycoprotein lyssavirus vaccines for coverage against rabies
WO2021102363A1 (en) * 2019-11-20 2021-05-27 The University Of North Carolina At Chapel Hill Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
US20250127871A1 (en) * 2021-09-30 2025-04-24 The University Of North Carolina At Chapel Hill Methods and compositions for recombinant dengue viruses for vaccine and diagnostic development
CN116716322B (zh) * 2023-05-12 2024-05-31 中山大学 一种denv-3全长感染性克隆及其构建方法与应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
JPS60500673A (ja) 1983-03-08 1985-05-09 コモンウエルス　セラム　ラボラトリ−ズ　コミツシヨン 抗原活性を有するアミノ酸配列
KR100278157B1 (ko) 1992-06-25 2001-01-15 장 스테판느 보조약을 함유하는 백신 조성물
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CU22683A1 (es) * 1997-01-15 2001-07-20 Inst De Medicina Tropical Pedro Kouri Epítopes de la proteína pre-m/m del virus del dengue, péptidos sintéticos, proteínas quiméricas y sus usos
US6432411B1 (en) * 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
AU2005327198B2 (en) 2004-07-09 2011-03-31 University Of North Carolina At Chapel Hill Viral adjuvants
IN2012DN03294A (es) * 2004-07-27 2015-10-23 Government Of The Us Secretary Of The Dept Of Health And Human Services Ct S For Disease Control And
JP4993301B2 (ja) * 2004-10-20 2012-08-08 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 日本脳炎ウイルスおよび西ナイルウイルスに対するワクチン
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
US10081795B2 (en) * 2010-03-24 2018-09-25 Research Development Foundation Flavivirus host range mutations and uses thereof
WO2011146933A2 (en) * 2010-05-21 2011-11-24 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Universal dengue virus sequences and methods of use
WO2012027473A2 (en) * 2010-08-24 2012-03-01 The University Of North Carolina At Chapel Hill Immunogenic compositions comprising alphavirus vectored dengue virus e protein antigens
EA201390874A1 (ru) 2010-12-14 2013-12-30 Нэшнл Юниверсити Оф Сингапур Моноклональное антитело человека со специфичностью к белку e вируса денге серотипа 1 и его применение
EP2768847A4 (en) 2011-10-20 2015-11-11 Us Gov Health & Human Serv DENGUE VIRUS E-GLYCOPROTEIN POLYPEPTIDES WITH MUTATIONS FOR ELIMINATING IMMUNOMINANT CROSS-REACTIVE EPITOPES
WO2013151764A1 (en) * 2012-04-02 2013-10-10 The University Of North Carolina At Chapel Hill Methods and compositions for dengue virus epitopes

Also Published As

Publication number Publication date
US20160257719A1 (en) 2016-09-08
CN105473603B (zh) 2019-10-25
CA2918644A1 (en) 2014-12-31
BR112015032388A8 (pt) 2020-01-14
AU2018278927A1 (en) 2019-01-17
CN110734500A (zh) 2020-01-31
JP2019195328A (ja) 2019-11-14
US10870682B2 (en) 2020-12-22
JP2016523912A (ja) 2016-08-12
KR20160027019A (ko) 2016-03-09
BR112015032388A2 (pt) 2017-07-25
CN105473603A (zh) 2016-04-06
EP3013852A4 (en) 2017-02-15
WO2014210358A1 (en) 2014-12-31
EP3013852B1 (en) 2019-06-19
US20190225654A1 (en) 2019-07-25
EP3013852A1 (en) 2016-05-04
US10053493B2 (en) 2018-08-21
MX365957B (es) 2019-06-20
MX2019007252A (es) 2019-08-16
AU2014302282A1 (en) 2016-02-11
EP3590955A1 (en) 2020-01-08
ES2745431T3 (es) 2020-03-02
JP6525984B2 (ja) 2019-06-05
SG11201510617WA (en) 2016-01-28
AU2014302282B2 (en) 2018-09-13

Similar Documents

Publication Publication Date Title
EA201490659A1 (ru) Вакцины против вируса гриппа и их применения
CL2017001610A1 (es) Anticuerpos humanos para hemagglutinina de influenza
EA201991715A1 (ru) Композиции, содержащие антитело к pdl1
MX2019007252A (es) Metodos y composiciones para vacunas del virus del dengue.
CY1121560T1 (el) Ανοσογονικη συνθεση
EA201891339A1 (ru) Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб
EA201591164A1 (ru) Вакцины против вируса гриппа и их применение
CR20160502A (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso
CY1124521T1 (el) Σκευασματα αντισωματος anti-cd19
MX2016003199A (es) Compuestos de azapiridona y usos de los mismos.
DK3408295T5 (da) Farmaceutisk sammensætning, som omfatter bispecifikke antistofkonstruktioner
CL2016002455A1 (es) Anticuerpos multiespecíficos.
MX2017005524A (es) Metodos y composiciones para el virus del dengue recombinante para el desarrollo de vacunas y de diagnostico.
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
EA201692467A1 (ru) Вакцины против вируса гриппа и их применения
MX376715B (es) Vacuna contra el virus de la diarrea epidemica porcina.
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
MX366180B (es) Nuevos agentes de union a ha.
MX2015016627A (es) Vacuna para la malaria.
EA201692541A1 (ru) Вакцины против вируса гриппа и их применения
MX2021010060A (es) Produccion de virus en huevos aviares.
ZA201703510B (en) Antibodies, uses & methods
CY1120759T1 (el) Παρασκευη διγλυκοζιτη (s,s)-σεκοϊσολαρικιρεσινολης και διγλυκοζιτη (r,r)-σεκοϊσολαρικιρεσινολης
MX2017011655A (es) Compuestos de aza-piridona y usos de estos.
BR112015017420A2 (pt) recombinação de vírus influenza

Legal Events

Date Code Title Description
FG Grant or registration